Carisma Therapeutics and OrthoCellix merge to focus on developing NeoCart technology for knee cartilage

From Yahoo Finance: 2025-06-24 13:07:00

Carisma Therapeutics and OrthoCellix, a subsidiary of Ocugen, have agreed to merge in an all-stock deal to focus on developing NeoCart technology for knee cartilage defects. NeoCart uses patient cells to grow chondrocytes for cartilage repair. A Phase 3 clinical trial is planned to begin by the end of 2025. The merger includes a private financing to fund the trial. Upon completion, Carisma will be renamed OrthoCellix and trade on Nasdaq under ‘OCLX.’ The deal is expected to close in the second half of 2025, pending approvals and a registration statement with the SEC. Directors and officers have agreed to vote in favor of the merger.



Read more at Yahoo Finance: Carisma Therapeutics, OrthoCellix enter definitive merger agreement